A new formulation of tenofovir that can be taken at lower doses
demonstrated potent activity against hepatitis B virus (HBV) similar to
that of the existing formulation in a 28-day study, but with less effect
on kidney function, researchers reported at the 64th AASLD Liver Meeting
this month in Washington, DC.
Gilead Science's tenofovir disoproxil fumarate (TDF, brand name Viread)—the currently marketed formulation—is one of the most effective
antiviral drugs for hepatitis B as well as one of the most widely used
antiretrovirals for HIV. TDF is generally safe and well-tolerated, but
it can cause kidney toxicity in susceptible individuals and is also
associated with bone loss.
Read more... Labels: tenofovir alafenamide (TAF)